InnovAATe (inhaled AAT) Phase 3 AATD lung disease
Trial setup
- Trial: InnovAATe, Phase 3, randomized, placebo-controlled. - Population: alpha-1 antitrypsin deficiency (AATD) with lung disease. - Interim monitoring: prespecified review may recommend stopping for futility.
Model leaderboard
How AI models scored forecasting this event. Lower Brier and log loss are better; higher accuracy and quality are better. Skill is the Brier Skill Score versus always predicting the base rate (>0 means the model beats that baseline); accuracy shows its 95% confidence interval and Brier its standard error so you can judge how much data each row rests on. Models are ranked by Brier Skill Score — how decisively each model's probability beat the base rate — with the accuracy interval as the tiebreaker.
No model results yet
This benchmark is open for forecasting. Run a model in the Arena to be among the first results recorded here.